Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 5/20 | 0.50 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.38 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 6/20 | 0.37 |
| ▸ | PPARD | Q03181 | 6/20 | 0.37 |
| ▸ | PPARA | Q07869 | 6/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29389884 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TSHRFFAR3HDAC3HDAC1 | |
| SCHEMBL14728237 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TSHRFFAR3HDAC3HDAC1 | |
| SCHEMBL17418301 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TSHRFFAR3HDAC3HDAC1 | |
| SCHEMBL19382679 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TSHRFFAR3HDAC3HDAC1 | |
| SCHEMBL16908570 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TSHRFFAR3HDAC3HDAC1 | |
| SCHEMBL14770377 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TSHRFFAR3HDAC3HDAC1 | |
| SCHEMBL22445118 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TSHRFFAR3HDAC3HDAC1 | |
| SCHEMBL22445105 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TSHRFFAR3HDAC3HDAC1 | |
| SCHEMBL21087133 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TSHRFFAR3HDAC3HDAC1 | |
| SCHEMBL29649576 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TSHRFFAR3HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3955937-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2022-02-23 | — | — | EP | claimed |
| WO-2020212760-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2020-10-22 | — | — | WO | claimed |
| US-20260007758-A1 | SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) NON-PEPTIDE DRUG CONJUGATES AND USES THEREOF | CRINETICS PHARMACEUTICALS INC (US) | 2026-01-08 | — | — | US | disclosed |
| EP-4659809-A2 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250361260-A1 | NUCLEOTIDE ANALOGUES | SINGULAR GENOMICS SYSTEMS INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4624466-A1 | DEGRADER FOR DECOMPOSING CMET PROTEIN, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Innocure Therapeutics, Inc. (KR) | 2025-10-01 | — | — | EP | disclosed |
| EP-3538539-B1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMA (US) | 2025-08-27 | — | — | EP | disclosed |
| US-12377159-B2 | Steroids and protein-conjugates thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-20250215117-A1 | METHOD FOR PRODUCING ESTERIFIED POLYSACCHARIDE | KOEI CHEMICAL COMPANY, LIMITED (JP) | 2025-07-03 | — | — | US | disclosed |
| EP-4578879-A1 | METHOD FOR PRODUCING ESTERIFIED POLYSACCHARIDE | Koei Chemical Company, Limited (JP) | 2025-07-02 | — | — | EP | disclosed |
| US-20250109090-A1 | METHOD FOR PRODUCING ONIUM SALT AND METHOD FOR PURIFYING ONIUM SALT | KOEI CHEMICAL COMPANY, LIMITED (JP) | 2025-04-03 | — | — | US | disclosed |
| WO-2016014846-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF INTRABODIES | MODERNA THERAPEUTICS, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
| US-20160015831-A1 | ANTI-CD22 ANTIBODY-DRUG CONJUGATES AND METHODS OF USING THEREOF | ABGENOMICS INTERNATIONAL INC. | 2016-01-21 | — | — | US | disclosed |
| WO-2016011306-A2 | TERMINAL MODIFICATIONS OF POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| US-20160009669-A1 | ONIUM SALT, LIQUID COMPOSITION CONTAINING SAID ONIUM SALT AND CELLULOSE, AND CELLULOSE RECOVERY METHOD | KOEI CHEMICAL COMPANY, LIMITED (JP) | 2016-01-14 | — | — | US | disclosed |
| CN-104837801-A | Onium salt, liquid composition containing onium salt and cellulose, and cellulose recovery method | KOEI CHEMICAL CO | 2015-08-12 | — | — | CN | disclosed |
| WO-2015023979-A1 | DISCRETE PEG CONSTRUCTS | EQUIP, LLC (US) | 2015-02-19 | — | — | WO | disclosed |
| US-7754105-B2 | Water-soluble preflux and usage of the same | SHIKOKU CHEMICALS CORPORATION (JP) | 2010-07-13 | — | — | US | disclosed |
| US-20080318070-A1 | Water-Soluble Preflux and Usage of the Same | SHIKOKU CHEMICALS CORPORATION (JP) | 2008-12-25 | — | — | US | disclosed |
| EP-1886759-A1 | WATER-SOLUBLE PREFLUX AND USE THEREOF | SHIKOKU CHEMICALS CORPORATION (JP) | 2008-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009669-A1 | ONIUM SALT, LIQUID COMPOSITION CONTAINING SAID ONIUM SALT AND CELLULOSE, AND CELLULOSE RECOVERY METHOD | CEL, CROCC, ALG1 | ALDH1A1 4797/4885TSHR 4776/4885FFAR3 3525/4885 |
| US-20160015831-A1 | ANTI-CD22 ANTIBODY-DRUG CONJUGATES AND METHODS OF USING THEREOF | CD22, CD2, CD2BP2 | ALDH1A1 215/4885TSHR 2591/4885FFAR3 3768/4885 |
| US-20250361260-A1 | NUCLEOTIDE ANALOGUES | ADAR, NUDT1, NSUN2 | ALDH1A1 1085/4885TSHR 2978/4885FFAR3 4431/4885 |
| US-20260007758-A1 | SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) NON-PEPTIDE DRUG CONJUGATES AND USES THEREOF | SSTR4, SSTR1, SSTR3 | ALDH1A1 2794/4885TSHR 26/4885FFAR3 53/4885 |
| US-20250109090-A1 | METHOD FOR PRODUCING ONIUM SALT AND METHOD FOR PURIFYING ONIUM SALT | NOTUM, CA7, CROCC | ALDH1A1 1777/4885TSHR 4312/4885FFAR3 955/4885 |
| US-12377159-B2 | Steroids and protein-conjugates thereof | SERPINA6, NR3C1, NR3C2 | ALDH1A1 4113/4885TSHR 809/4885FFAR3 3895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.